Inovio Pharmaceuticals released a preliminary financial update for the third quarter ended September 30, 2026, focusing on its liquidity position. The report serves as a limited disclosure of current assets prior to the full quarterly earnings release.
Key Highlights
- Preliminary cash, cash equivalents, and short-term investments were estimated at $48.4 million at the end of the third quarter.
- The reported figures are unaudited management estimates and remain subject to final financial closing procedures.
- No operating results, including revenue or net loss figures, were provided in this specific filing.